Michael D Kaytor
Overview
Explore the profile of Michael D Kaytor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
751
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Serebrenik A, Fatanmi O, Wise S, Petrus S, Kaytor M, Singh V
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201502
Development of radiation medical countermeasures under the U.S. Food and Drug Administration Animal Rule requires the capability to translate an effective animal-to-human drug dose. One method of human dose translation...
2.
Singh V, Serebrenik A, Wise S, Petrus S, Fatanmi O, Kaytor M
Mil Med
. 2024 Aug;
189(Suppl 3):390-398.
PMID: 39160790
Introduction: Exposure to high doses of ionizing radiation can result in hematopoietic acute radiation syndrome. Currently, there is no radiation medical countermeasure approved by the U.S. FDA which can be...
3.
Simone 2nd C, Serebrenik A, Gore E, Mohindra P, Brown S, Wang D, et al.
Int J Radiat Oncol Biol Phys
. 2023 Aug;
118(2):404-414.
PMID: 37652301
Purpose: Radiation therapy is part of the standard treatment regimen for non-small cell lung cancer (NSCLC). Although radiation therapy is an effective tool to manage NSCLC, it can be associated...
4.
Kaytor M, Serebrenik A, Lapanowski K, McFall D, Jones M, Movsas B, et al.
Transl Lung Cancer Res
. 2023 Jun;
12(5):999-1010.
PMID: 37323169
Background: Radiotherapy for non-small cell lung cancer (NSCLC) can be dose-limiting due to treatment-related toxicities. Genistein has been shown to be a robust radioprotective agent in preclinical models. A novel...
5.
Gibbs A, Gupta P, Mali B, Poirier Y, Gopalakrishnan M, Newman D, et al.
Radiat Res
. 2023 Mar;
199(4):319-335.
PMID: 36857032
The objective of the current study was to establish a mouse model of acute radiation syndrome (ARS) after total-body irradiation with 2.5% bone marrow sparing (TBI/BM2.5) that progressed to the...
6.
Singh V, Serebrenik A, Fatanmi O, Wise S, Carpenter A, Janocha B, et al.
Radiat Res
. 2023 Jan;
199(3):294-300.
PMID: 36689635
Acute exposure to high dose radiation can cause acute radiation syndrome (ARS), a potentially life-threatening illness. Individuals that survive ARS are at risk of developing the delayed effects of acute...
7.
Serebrenik A, Verduyn C, Kaytor M
Clin Pharmacol Drug Dev
. 2022 Oct;
12(2):190-201.
PMID: 36301689
A pharmaceutical formulation of genistein, produced as an amorphous solid dispersion by hot melt extrusion (genistein HME), has been developed that can be administered prophylactically to improve outcomes and survival...
8.
Li Y, Girgis M, Jayatilake M, Serebrenik A, Cheema A, Kaytor M, et al.
Sci Rep
. 2022 Aug;
12(1):13475.
PMID: 35931769
BIO 300, a pharmaceutical formulation of genistein, is being developed as a radiation countermeasure to treat hematopoietic acute radiation syndrome (H-ARS) and the delayed effects of acute radiation exposure (DEARE)....
9.
Salem A, Jackson I, Gibbs A, Poirier Y, Newman D, Zodda A, et al.
Radiat Res
. 2022 Feb;
197(5):447-458.
PMID: 35119453
BIO 300, a suspension of synthetic genistein nanoparticles, is being developed for mitigating the delayed effects of acute radiation exposure (DEARE). The purpose of the current study was to characterize...
10.
Cheema A, Li Y, Singh J, Johnson R, Girgis M, Wise S, et al.
Anim Microbiome
. 2021 Oct;
3(1):71.
PMID: 34627406
Background: The mammalian gut harbors very complex and diverse microbiota that play an important role in intestinal homeostasis and host health. Exposure to radiation results in dysbiosis of the gut...